Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

120.79 +2.95 (+2.50%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,120,521
Open 117.90
Bid (Size) 119.76 (4)
Ask (Size) 121.97 (1)
Prev. Close 117.84
Today's Range 116.25 - 120.98
52wk Range 61.28 - 134.08
Shares Outstanding 87,782,576
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
9 Analysts Have This to Say About Sarepta Therapeutics
 
Via Benzinga

Performance

YTD
-3.24%
-3.24%
1 Month
+2.77%
+2.77%
3 Month
+20.32%
+20.32%
6 Month
+8.36%
+8.36%
1 Year
+59.04%
+59.04%

More News

Read More
7 Biotech Stocks That Will Make You Rich in 10 Years
Via InvestorPlace
2 Under-the-Radar Biotech Stocks to Buy in 2023
Via The Motley Fool
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
From Catalent, Inc.
Via Business Wire
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
Via Benzinga
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
Via The Motley Fool
2 Top Healthcare Stocks to Buy for the Long Haul
Via The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
Via Investor's Business Daily
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
Via Investor's Business Daily
3 Unstoppable Stocks That Could Double in 5 Years
Via The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
Via The Motley Fool
7 Analysts Have This to Say About Sarepta Therapeutics
Via Benzinga
Analyst Ratings for Sarepta Therapeutics
Via Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
Via Benzinga
Earnings Scheduled For November 2, 2022
Via Benzinga
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
Via Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
Via MarketBeat
Exposures COVID-19
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
Via AB Newswire
A Trio of Q3 Winners With Room to Run
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
Via Benzinga
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.